Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An IDH-mutant, and 1p/19q-codeleted oligodendroglioma that is characterized as a well differentiated tumor lacking anaplastic features (brisk mitotic activity, microvascular proliferation, necrosis).
Biomarker and diagnostic research for oligodendroglioma, IDH-mutant and 1p/19q-codeleted grade 2 has been reported in the published literature.
No clinical trials have been registered for oligodendroglioma, IDH-mutant and 1p/19q-codeleted grade 2.
25 publications have been identified in PubMed for oligodendroglioma, IDH-mutant and 1p/19q-codeleted grade 2. Research spans Clinical Trial Publication (28%), Review / Meta-Analysis (24%), and Basic Science / Preclinical (24%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 7 | 28% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 3:03 AM UTC
Research summaries |
6 |
24% |
Laboratory research | 6 | 24% |
Testing and diagnosis research | 4 | 16% |
Patient case studies | 1 | 4% |
Disease patterns and progression | 1 | 4% |
Müther M (2026). [PMID: 40926130](https://pubmed.ncbi.nlm.nih.gov/40926130/). *European journal of nuclear medicine and molecular imaging*. [Basic Science / Preclinical]
Karsonovich T (2026). [PMID: 32809503](https://pubmed.ncbi.nlm.nih.gov/32809503/). *Unknown Journal*. [Review / Meta-Analysis]
Ozono I (2026). [PMID: 41189118](https://pubmed.ncbi.nlm.nih.gov/41189118/). *Japanese journal of clinical oncology*. [Clinical Trial Publication]
Hata N (2026). [PMID: 41890358](https://pubmed.ncbi.nlm.nih.gov/41890358/). *Neurooncol Adv*. [Clinical Trial Publication]
Rincon-Torroella J (2025). [PMID: 39382617](https://pubmed.ncbi.nlm.nih.gov/39382617/). *Journal of neuro-oncology*. [Clinical Trial Publication]
Nozzoli F (2025). [PMID: 40692489](https://pubmed.ncbi.nlm.nih.gov/40692489/). *Neuro-oncology*. [Basic Science / Preclinical]
Bao J (2025). [PMID: 40448901](https://pubmed.ncbi.nlm.nih.gov/40448901/). *Discover oncology*. [Review / Meta-Analysis]
Gatto L (2025). [PMID: 41153666](https://pubmed.ncbi.nlm.nih.gov/41153666/). *Biomedicines*. [Clinical Trial Publication]
Imai N (2025). [PMID: 41095858](https://pubmed.ncbi.nlm.nih.gov/41095858/). *Journal of clinical medicine*. [Diagnostic / Biomarker]
Nakashima T (2025). [PMID: 41140994](https://pubmed.ncbi.nlm.nih.gov/41140994/). *Cureus*. [Case Report / Case Series]